AxoGen, Inc (NASDAQ:AXGN) saw a significant decline in short interest in January. As of January 31st, there was short interest totalling 1,660,000 shares, a decline of 18.6% from the January 15th total of 2,040,000 shares. Based on an average daily trading volume, of 355,000 shares, the short-interest ratio is presently 4.7 days. Currently, 4.7% of the company’s stock are sold short.

Several hedge funds have recently modified their holdings of the company. Bank of America Corp DE increased its position in shares of AxoGen by 13.7% during the fourth quarter. Bank of America Corp DE now owns 873,582 shares of the medical equipment provider’s stock worth $15,628,000 after purchasing an additional 104,964 shares in the last quarter. Jacobs Levy Equity Management Inc. acquired a new position in shares of AxoGen during the fourth quarter worth $1,170,000. ArrowMark Colorado Holdings LLC increased its position in shares of AxoGen by 11.0% during the fourth quarter. ArrowMark Colorado Holdings LLC now owns 5,978,578 shares of the medical equipment provider’s stock worth $106,957,000 after purchasing an additional 594,752 shares in the last quarter. UBS Group AG increased its position in shares of AxoGen by 12.2% during the fourth quarter. UBS Group AG now owns 16,727 shares of the medical equipment provider’s stock worth $299,000 after purchasing an additional 1,815 shares in the last quarter. Finally, Mairs & Power INC increased its position in shares of AxoGen by 46.7% during the fourth quarter. Mairs & Power INC now owns 22,000 shares of the medical equipment provider’s stock worth $394,000 after purchasing an additional 7,000 shares in the last quarter. 82.77% of the stock is currently owned by institutional investors and hedge funds.

Shares of AXGN stock traded up $0.56 during trading hours on Friday, reaching $14.02. 332,500 shares of the company’s stock were exchanged, compared to its average volume of 331,487. The stock’s 50 day moving average is $14.70 and its 200-day moving average is $14.86. The company has a market cap of $523.36 million, a price-to-earnings ratio of -20.32 and a beta of 0.33. The company has a current ratio of 8.20, a quick ratio of 7.38 and a debt-to-equity ratio of 0.01. AxoGen has a fifty-two week low of $10.91 and a fifty-two week high of $25.84.

A number of brokerages recently commented on AXGN. ValuEngine downgraded shares of AxoGen from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, January 8th. BidaskClub raised shares of AxoGen from a “strong sell” rating to a “sell” rating in a research note on Thursday, February 6th. Finally, BTIG Research reaffirmed a “buy” rating and set a $21.00 price target on shares of AxoGen in a research report on Monday, December 16th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the company. The stock presently has an average rating of “Buy” and an average target price of $25.00.

About AxoGen

AxoGen, Inc develops and markets surgical solutions for peripheral nerve injuries. The company's surgical solutions include Avance Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments.

Further Reading: Real Estate Investment Trust (REIT) ETF

Receive News & Ratings for AxoGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AxoGen and related companies with MarketBeat.com's FREE daily email newsletter.